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Abstract. Methotrexate is an antimetabolite
indications ranging from rheumatoid arthritis and other connective tissue disorders to high dose 
regimens in many malignancies. This folate antagonist has got a spectrum of toxicities among which 
gastrointestinal effects predominate. 
reported most often in patients who have been on long term oral therapy for rheumatic disorders. 
Acute lung injury in a patient receiving a high dose regimen for hae
not been reported previously.  We present one such case of methotrexate related acute lung injury 
in a patient of primary CNS lymphoma receiving high dose methotrexate.
Introduction. Methotrexate has a broad  spectrum of 
side  effects  ranging  from  gastrointestinal  and 
haematological dysfunction  to  the  less  commonly 
described lung injury. The most commonly associated 
lung injury described in association with methotrexate 
use is pulmonary fibrosis that has been seen in patients 
who  have  been  receiving  long  term  oral  therapy for 
rheumatoid arthritis. Less well known is the syndrome 
of acute lung injury that is seen in patients who are 
treated  with  high  dose  regimens  as  used  in  the 
management  of  osteosarcoma  or  haematological 
malignancies. Due to the already immunocompromised 
nature  of  these  patients,  it  is  important  to  clinically 
differentiate this potentially life threatening syndrome 
from  other  causes  of  acute  lung  injury  such  as 
bacterial, viral and fungal infections. 
Case Report. A 58- year- old female was admitted to a 
tertiary care centre in northern India for the  treatment 
; Open Journal System
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
www.mjhid.org ISSN 2035-3006
Methotrexate Induced Lung Injury in a Patient with Primary CNS Lymphoma: 
, Vikas Suri, Pankaj Malhotra* and Subhash Varma
GIMER Chandigarh 160012, India
Pankaj Malhotra. E-mail: malhotrapankaj@hotmail.com
have declared that no competing interests exist.
e2012020, DOI 10.4084/MJHID.2012.020
http://www.mjhid.org/article/view/9884
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, 
cited.
Methotrexate is an antimetabolite commonly used in clinical practice for a variety of 
indications ranging from rheumatoid arthritis and other connective tissue disorders to high dose 
regimens in many malignancies. This folate antagonist has got a spectrum of toxicities among which 
predominate. Lung injury is a well described but rare event and has been 
reported most often in patients who have been on long term oral therapy for rheumatic disorders. 
Acute lung injury in a patient receiving a high dose regimen for haematological malignancies has 
not been reported previously.  We present one such case of methotrexate related acute lung injury 
in a patient of primary CNS lymphoma receiving high dose methotrexate.
Methotrexate has a broad  spectrum of 
side  effects  ranging  from  gastrointestinal  and 
dysfunction  to  the  less  commonly 
described lung injury. The most commonly associated 
lung injury described in association with methotrexate 
use is pulmonary fibrosis that has been seen in patients 
who  have  been  receiving  long  term  oral  therapy for 
oid arthritis. Less well known is the syndrome 
of acute lung injury that is seen in patients who are 
treated  with  high  dose  regimens  as  used  in  the 
management  of  osteosarcoma  or  haematological 
malignancies. Due to the already immunocompromised 
ese  patients,  it  is  important  to  clinically 
differentiate this potentially life threatening syndrome 
from  other  causes  of  acute  lung  injury  such  as 
old female was admitted to a 
re centre in northern India for the  treatment 
of primary CNS lymphoma. She was diagnosed on the 
basis of neuroimaging and a stereotactic brain biopsy 
which showed diffuse large B cell lymphoma. PET CT 
confirmed  isolated  CNS  involvement.  At  admission 
she had an ECOG performance status of 4 because of 
the  disease  and  neurosurgical  intervention.  Initially, 
CSF  cytology  was  negative  for  malignant  cells.  
Baseline high resolution CT chest was normal. 
The  patient  was  started  on  DeAngelis  protocol 
which  included five  cycles of  high  dose  intravenous 
methotrexate  and  vincristine,  oral  procarbazine  and 
intrathecal  methotrexate  preceding  whole  brain 
irradiation  and  post  radiation 
poor performance status, a lower dose 
(1gm/m
2) was given in the first cycle. Four days after 
receiving  the  first  cycle  she  developed  fever  and 
shortness  of  breath.    Physical  examination  revealed 
presence  of  bibasilar  crepts.  Chest  roentgenogram 
revealed  bilateral  lower  zone infiltrates.  Blood gases 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Primary CNS Lymphoma: a
Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, 
commonly used in clinical practice for a variety of 
indications ranging from rheumatoid arthritis and other connective tissue disorders to high dose 
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Figure 1. Figure showing normal tracheobronchial tree, vessels and 
normal lung parenchyma.
revealed hypoxia at room air.  She was given injectable 
broad spectrum antibiotics and supplemental  oxygen. 
All cultures (bacterial, fungal, viral) were
glucan  was  negative  and  the  patient  had  a  gradual 
improvement in symptoms over the next week. After 
the first cycle, CSF examination was repeated as per 
protocol  and  was  positive  for  malignant  cells. 
Accordingly, a  decision  was taken  to  give  the  usual 
dose of methotrexate (3.5 gm/m
2) in the next cycle
day  after  receiving  methotrexate  administration,  the 
patient  again  developed  breathlessness.  Examination 
revealed diffuse bronchospasm and crepitations in both 
lung fields. She had no fever throughout this 
High  resolution  CT  of  the  chest  revealed  bilateral 
patchy  ground  glass  opacification  as  well  as  basal 
atelectasis .
Blood  gases  revealed  severe  hypoxemia,  cultures 
were sterile, fungal and viral serologies were negative
and    patient  had  remained  afebrile  throughout  this 
episode. A possibility of drug induced lung injury was 
kept. On the basis of clinical criteria devised by Searles 
and  Mckendry  the  patient  was  diagnosed  with 
methotrexate induced lung injury.
1 She was managed 
with intravenous and inhaled corticosteroids in addition 
to  inhaled  bronchodilators.  She  improved  with  this 
management  and  was  taken  off  oxygen  after  two 
weeks. Due to methotrexate toxicity further high dose 
chemotherapy  was  deferred  and  she  was  advised  to 
proceed  with  radiation  therapy.  She  was 
temozolomide therapy post  whole brain radiotherapy
She remains on close follow- up one year later. Serial 
PET CT scans have shown remission of lymphoma and 
no recurrence after one year. No progression of lung 
injury or any fibrotic changes have been seen.
Discussion.  Methotrexate  is  an  antimetabolite  acting 
via folate inhibition. Therefore, it acts on tissues which 
have  high  rates  of  cellular  division  such  as  skin, 
gastrointestinal  tract,  liver  and  bone  marrow.  It  is 
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Figure showing normal tracheobronchial tree, vessels and 
revealed hypoxia at room air.  She was given injectable 
broad spectrum antibiotics and supplemental  oxygen. 
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weeks. Due to methotrexate toxicity further high dose 
chemotherapy  was  deferred  and  she  was  advised  to 
therapy.  She  was  put  on 
whole brain radiotherapy. 
up one year later. Serial 
PET CT scans have shown remission of lymphoma and 
no recurrence after one year. No progression of lung 
tic changes have been seen.
Methotrexate  is  an  antimetabolite  acting 
via folate inhibition. Therefore, it acts on tissues which 
have  high  rates  of  cellular  division  such  as  skin, 
gastrointestinal  tract,  liver  and  bone  marrow.  It  is 
Figure 2.
Figure 3.
Figure 4.
Figure  2,3,4. HRCT  chest  [after  giving  methotrexate],  showing 
normal  tracheobronchial  tree,  vessels  but  lung  parenchymal 
changes in the form of  b/l patchy ground glass opacities with b/l 
basal atelectasis.
highly  teratogenic  and  is  classified  as  a  category  X 
drug in pregnancy. The effect of methotrexate
lungs is less well studied. The spectrum of pulmonary 
toxicities  involves  hypersensitivity  pneumonitis
interstitial fibrosis, pulmonary edema,
airway  hyperreactivity,  bronchiolitis  obliterans  with 
organizing  pneumonia  (BOOP)  and 
nodules.
4 The  symptoms are  nonspecific  and include 
nonproductive cough, shortness of breath, chest pain 
and vague constitutional symptoms. The time of onset 
of  symptoms  after  administration  of  methotrexate  is 
highly  variable.The  injury  does  not  a
dependent  upon  the  dose.  C
HRCT  chest  [after  giving  methotrexate],  showing 
normal  tracheobronchial  tree,  vessels  but  lung  parenchymal 
changes in the form of  b/l patchy ground glass opacities with b/l 
highly  teratogenic  and  is  classified  as  a  category  X 
drug in pregnancy. The effect of methotrexate on the 
lungs is less well studied. The spectrum of pulmonary 
toxicities  involves  hypersensitivity  pneumonitis,
2
interstitial fibrosis, pulmonary edema,
3 bronchitis with 
airway  hyperreactivity,  bronchiolitis  obliterans  with 
organizing  pneumonia  (BOOP)  and  pulmonary 
The  symptoms are  nonspecific  and include 
nonproductive cough, shortness of breath, chest pain 
and vague constitutional symptoms. The time of onset 
of  symptoms  after  administration  of  methotrexate  is 
highly  variable.The  injury  does  not  appear  to  be 
.  Cases  have  been  reportedMediterr J Hematol Infect Dis 2012; 4: Open Journal System
Carson et al. 1987
Clinical
1.  Clinical  course  consistent  with 
hypersensitivity
Radiology
2.  Resolving  infiltrates  on  chest 
roentgenogram(CXR) after  discontinuing
methotrexate
Infection exclusion
3. Exclusion of infection or other pulmonary
disease
Histology
4. Pathology consistent with drug induced
injury (i.e. hypersensitivity pneumonitis or
toxic drug reaction)
3 or 4 out of the above 4 =Probable MTX-P
2 of above =Possible MTX P
1 of above=Unlikely MTX-P
Searles et al. 1987
Clinical
1. Acute onset of dyspnoea
2. Fever >38
0c
3. Tachypnoea 28/min and non-
productive cough
Laboratory
4. WBC 15 X 10
9/L (+/- eosinophilia)
5. PO2 on room air <55mm/Hg at 
admission
Infection
6. Negative blood and sputum cultures 
(obligatory)
Radiological
7. Pulmonary interstitial or alveolar 
infiltrates
Pulmonary function tests
8. Restrictive pattern, decreased diffusion
Histopathology
9. Bronchiolitis/interstitial pneumonitis 
with giant cells without evidence of 
pathogenic microorganisms
6 out of 9 criteria : Definite MTX-P
5 out of 9 criteria : Probable MTX-P
4 out of 9 criteria : Possible MTX-P
Kremer et al. 1997
Major criteria
Histology
1. Hypersensitivity pneumonitis by 
histopathological examination
Radiology
2. Radiologic evidence of pulmonary 
interstitial or alveolar infiltrates
Infection
3. Blood (if febrile) cultures ad initial 
sputum (if produced) cultures negative for 
pathogenic organisms*
Minor criteria
Clinical
1. Shortness of breath<8 weeks
2. Dry cough
Laboratory
3. O2 saturation <90%
4. WBC < 15, 000/mm
3
Pulmonary fuction tests
5. DLCO 70% predicted
*microbiological criteria met if afebrile and 
no sputum production
Definite case of MTX-P:
Major criteria 1
Major criteria 2 and 3 and at least 3 minor 
criteria
Probable case of MTX-P:
Major criteria 2 and 3, and 2 minor criteria
where injury has occurred with doses as low as 7.5 mg 
to  as  high  as  3600 mg.  Even  a  single  dose  of 
methotrexate has been known to cause lung injury.The 
mechanism of lung injury has not been studied in detail 
however  few  studies  have  shown  that  cytokine 
modulation via P38-MAP kinase pathway may play an 
important role.
5 It was also thought that polymorphism 
in the methylenetetrahydrofolate genes may be linked 
with  methotrexate  toxicity.  Some  studies  show  that 
polymorphism of the C677T methylenetetrahydrofolate 
gene  is  associated  with  increased  toxicity  of 
methotrexate  while  others  do  not.
6,7  However  a  few 
more  studies are  required  to  prove  the  association 
between methylenetetrahydrofolate polymorphism and 
methotrexate  toxicity.  As  most  patients  receiving 
methotrexate are also susceptible to infections due to 
their  underlying  disease,  investigation  for  infectious 
causes of lung injury should be done in all patients. 
Bronchoalveolar lavage is important to rule out other 
infective  etiologies  however  the  findings  in 
methotrexate induced lung injury are nonspecific and 
reveal a lymphocytic infiltrate. Radiographic findings 
reveal bilateral alveolar and interstitial infiltrate which 
are  common  in  bibasilar  regions  but  may  be 
unremarkable.
8,9,10 Lung biopsy reveals the presence of 
lymphocytes  although  occasional  neutrophilic 
infiltrates  may  also  be  present.
11 Eosinophilia, 
hyperplasia  of  Type  2  pneumocytes  and  interstitial 
fibrosis have also been described. Due to the absence 
of  specific  clinical,  radiological  and  pathological 
findings,  it  is  important  to  have  a  high  index  of 
suspicion  and  rule  out  other  more  common  causes. 
Several criteria have been devised by Carson, Searle  
and Kremer (Table 1). Treatment involves withdrawal 
of  methotrexate  and  administration  of  steroids. 
Spontaneous  resolution  despite  continuation  of  the 
drug has also been described.
12 Restarting methotrexate
may  lead  to  recurrence  of  lung  injury  although 
successful reintroduction of oral methotrexate has been 
described in two cases.
13 Leucovorin rescue does not 
protect  against  methotrexate  induced  lung  damage. 
Most patients have an uneventful recovery following 
lung injury,
14 however, some may have persistent lung 
damage causing fibrosis and restrictive lung disease.
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